Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by V.V. Baykov
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma
European Journal of Medical Research
Medicine
High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience
Acta Haematologica Polonica
Oncology
Hematology
PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
New England Journal of Medicine
Medicine
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Leucocyte and Eosinophil Counts Predict Progression-Free Survival in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated With PD1 Inhibition
British Journal of Haematology
Hematology
Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin
British Journal of Haematology
Hematology
